{
    "Trade/Device Name(s)": [
        "RIGHTEST Blood Glucose Monitoring System Max Tel",
        "RIGHTEST Meter Max Tel",
        "RIGHTEST Blood Glucose Test Strip Max",
        "RIGHTEST Blood Glucose Meter Max Tel",
        "RIGHTEST Control Solution GC700"
    ],
    "Submitter Information": "Bionime Corporation",
    "510(k) Number": "K240637",
    "Predicate Device Reference 510(k) Number(s)": [
        "K231192"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "November 4, 2024",
    "Summary Letter Received Date": "October 3, 2024",
    "Submission Date": "October 3, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "RIGHTEST Blood Glucose Meter Max Tel"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric detection",
        "Dehydrogenase electrochemical sensor"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "Test Strip",
        "Control Solution",
        "Lancing Device",
        "Sterile Lancets"
    ],
    "Document Summary": "FDA 510(k) summary for RIGHTEST Blood Glucose Monitoring System Max Tel, an OTC glucose test system using amperometric detection.",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood from fingertip, forearm, or palm for self-testing by individuals with diabetes, to monitor effectiveness of diabetes control (not for diagnosis or neonatal use).",
    "fda_folder": "Clinical Chemistry"
}